BET inhibitors are efficacious in models of NUT midline carcinoma (NMC), a rare epithelial tumor type driven by the fusions of NUT protein with either BRD3 or BRD4 genes [7]. This evidence concerns the gene BRD4 and nut midline carcinoma.